HEPATO CELLULAR CARCINOMA (HCC)
Clinical trials for HEPATO CELLULAR CARCINOMA (HCC) explained in plain language.
Never miss a new study
Get alerted when new HEPATO CELLULAR CARCINOMA (HCC) trials appear
Sign up with your email to follow new studies for HEPATO CELLULAR CARCINOMA (HCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New strategy aims to stop liver cancer from coming back
Disease control Not yet recruitingThis study is testing if giving an immunotherapy drug called atezolizumab before surgery to remove liver cancer can help prevent the cancer from returning. Researchers want to see if boosting the patient's immune system before the operation is more effective than surgery alone. T…
Matched conditions: HEPATO CELLULAR CARCINOMA (HCC)
Phase: PHASE3 • Sponsor: University of Geneva, Switzerland • Aim: Disease control
Last updated Apr 02, 2026 01:11 UTC
-
New drug combo tested for Tough-to-Treat cancers
Disease control Not yet recruitingThis study is testing a new drug, WGI-0301, given together with an existing immunotherapy drug called nivolumab. It aims to see if this combination is safe and shows early signs of helping people with advanced liver cancer or advanced kidney cancer that has stopped responding to …
Matched conditions: HEPATO CELLULAR CARCINOMA (HCC)
Phase: PHASE2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Smart trial aims to match liver cancer patients with best next treatment
Disease control Not yet recruitingThis study is testing several new treatment combinations for people with advanced liver cancer whose first treatment stopped working. It uses a flexible design that quickly identifies which treatments show promise and which don't, while also looking for biological markers that mi…
Matched conditions: HEPATO CELLULAR CARCINOMA (HCC)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New combo therapy aims to stop liver cancer from coming back
Disease control Not yet recruitingThis study tests different combinations of treatments given before surgery for liver cancer that can be removed. The goal is to see if adding immunotherapy drugs and/or a targeted drug to standard local treatments (like TACE or ablation) can help keep the cancer from returning af…
Matched conditions: HEPATO CELLULAR CARCINOMA (HCC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC